Pure Global
NCT06341309

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Exploratory Study of Irinotecan Liposomes Combined With Bevacizumab in Maintenance Therapy of Metastatic Colorectal Cancer
West China Hospital·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Irinotecan Liposome
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
West China Hospital
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 01, 2024
End date
Aug 01, 2026
Enrollment
20 participants
Primary outcome

Progression free survival -1

Summary

To evaluate the progression-free survival (PFS1), objective response rate (ORR), disease
 control rate (DCR), progression-free survival from first-line treatment initiation (PFS2),
 overall survival (OS), and safety of irinotecan liposome combined with bevacizumab in
 patients with advanced metastatic colorectal cancer.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06341309
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06341309 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.